Literature DB >> 19854128

Targeting HSP70 for cancer therapy.

Lorenzo Galluzzi1, Fabrizio Giordanetto, Guido Kroemer.   

Abstract

In a recent issue of Molecular Cell, Leu et al. (2009) demonstrate that a chemical inhibitor of HSP70 exerts prominent tumor-selective cytotoxic effects, thereby lending further support to the notion that non-oncogene addiction constitutes a promising target for anticancer therapy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19854128     DOI: 10.1016/j.molcel.2009.10.003

Source DB:  PubMed          Journal:  Mol Cell        ISSN: 1097-2765            Impact factor:   17.970


  26 in total

Review 1.  Protein folding in the cytoplasm and the heat shock response.

Authors:  R Martin Vabulas; Swasti Raychaudhuri; Manajit Hayer-Hartl; F Ulrich Hartl
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-12       Impact factor: 10.005

2.  Phage display biopanning identifies the translation initiation and elongation factors (IF1α-3 and eIF-3) as components of Hsp70-peptide complexes in breast tumour cells.

Authors:  Christina Siebke; Tharappel C James; Robert Cummins; Tony O'Grady; Elaine Kay; Ursula Bond
Journal:  Cell Stress Chaperones       Date:  2011-10-16       Impact factor: 3.667

3.  Blockade of HSP70 by VER-155008 synergistically enhances bortezomib-induced cytotoxicity in multiple myeloma.

Authors:  Lingjuan Huang; Yanmeng Wang; Ju Bai; Yun Yang; Fangxia Wang; Yuandong Feng; Ru Zhang; Fangmei Li; Peihua Zhang; Nan Lv; Lei Lei; Jinsong Hu; Aili He
Journal:  Cell Stress Chaperones       Date:  2020-02-06       Impact factor: 3.667

4.  HtrA2, taming the oncogenic activities of WT1.

Authors:  Jörg Hartkamp; Stefan G E Roberts
Journal:  Cell Cycle       Date:  2010-07-01       Impact factor: 4.534

5.  Intracellular refolding assay.

Authors:  Tamara Vanessa Walther; Danilo Maddalo
Journal:  J Vis Exp       Date:  2012-01-24       Impact factor: 1.355

6.  Harnessing the cell death pathway for targeted cancer treatment.

Authors:  Christina K Speirs; Misun Hwang; Sungjune Kim; Weier Li; Sophia Chang; Vinod Varki; Lauren Mitchell; Stephen Schleicher; Bo Lu
Journal:  Am J Cancer Res       Date:  2010-09-30       Impact factor: 6.166

7.  A phase I study of PF-04929113 (SNX-5422), an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumor malignancies and lymphomas.

Authors:  Arun Rajan; Ronan J Kelly; Jane B Trepel; Yeong Sang Kim; Sylvia V Alarcon; Shivaani Kummar; Martin Gutierrez; Sonja Crandon; Wadih M Zein; Lokesh Jain; Baskar Mannargudi; William D Figg; Brett E Houk; Michael Shnaidman; Nicoletta Brega; Giuseppe Giaccone
Journal:  Clin Cancer Res       Date:  2011-09-09       Impact factor: 12.531

8.  The role of TXNDC5 in castration-resistant prostate cancer-involvement of androgen receptor signaling pathway.

Authors:  L Wang; G Song; X Chang; W Tan; J Pan; X Zhu; Z Liu; M Qi; J Yu; B Han
Journal:  Oncogene       Date:  2014-12-15       Impact factor: 9.867

9.  Targeting the hsp70 gene delays mammary tumor initiation and inhibits tumor cell metastasis.

Authors:  J Gong; D Weng; T Eguchi; A Murshid; M Y Sherman; B Song; S K Calderwood
Journal:  Oncogene       Date:  2015-02-09       Impact factor: 9.867

10.  Examination of Gossypol-Pluronic Micelles as Potential Radiosensitizers.

Authors:  Keishiro Tomoda; Carol Chiang; Kevin R Kozak; Glen S Kwon
Journal:  AAPS J       Date:  2015-08-06       Impact factor: 4.009

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.